Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: A meta-analysis

Respirology

Volumn 16, Issue 2, 2011, Pages 350-358

  Wang, Jianmiao ^a   Jin, Di ^a,b   Zuo, Peng ^a   Wang, Tao ^a   Xu, Yongjian ^a   Xiong, Weining ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Hubei College of Chinese Medicine   (China)

Author keywords

chronic obstructive pulmonary disease; formoterol; meta analysis; tiotropium

Indexed keywords

ARFORMOTEROL; FORMOTEROL; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; RHINOPHARYNGITIS; TRANSITIONAL DYSPNOEA INDEX; TREATMENT DURATION; XEROSTOMIA;

ADULT; AGED; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES;

EID: 79551542010     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01912.x     Document Type: Article

References (23)

1. Murray CJL, Lopez AD,. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349: 1498-504.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Report of the GOLD Workshop: Global Strategy for Diagnosis, Management and Prevention of COPD. Updated 2009. [Accessed 15 Mar 2010.] Available from URL
3. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61: 854-62.
4. Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin. Ther. 2007; 29: 261-78.
5. Hanrahan J, Hanania NA, Calhoun WJ, et al. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD 2008; 5: 25-34.
6. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R,. Safety of long-acting β-agonists in stable COPD: a systematic review. Chest 2008; 133: 1079-87.
7. Keam SJ, Keating GM,. Tiotropium bromide: a review of its use as maintenance therapy in patients with COPD. Treat. Respir. Med. 2004; 3: 247-68.
8. Anderson GP, Linden A, Rabe KF,. Why are long-acting beta-adrenoceptor agonists long-acting? Eur. Respir. J. 1994; 7: 569-78.
9. Tashkin DP, Cooper CB,. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249-59.
10. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 3: CD006101.
11. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-8.
12. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
13. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
14. Cazzola M, Noschese P, Salzillo A, et al. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir. Med. 2005; 99: 524-8.
15. Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. 2004; 17: 35-9.
16. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6: 17-25.
17. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 2005; 26: 214-22.
18. Hanania NA, Boota A, Kerwin E, et al. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs 2009; 69: 1205-16.
19. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir. Med. 2008; 102: 479-87.
20. Terzano C, Petroianni A, Conti V, et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir. Med. 2008; 102: 1701-7.
21. Tashkin DP, Donohue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir. Med. 2009; 103: 516-24.
22. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-17.
23. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir. Med. 2008; 102: 1511-20.